Drug intelligence / Profile preview

TGRX-1942

Development stage: Phase 1
Lead developer: TargetRx
Modality: Small Molecules
Administration: Oral

Overview

TGRX-1942 is a novel small molecule inhibitor targeting protein-tyrosine kinase 7 (PTK7), a receptor tyrosine kinase implicated in cancer cell signaling and tumor progression. It is being developed by Shenzhen TargetRx for the treatment of various malignancies, including advanced solid tumors and relapsed or refractory hematologic cancers. The drug acts as an antagonist to PTK7, disrupting pathways critical for tumor growth and survival. As of June 2025, it is in phase I clinical trials evaluating its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors (such as non-small cell lung cancer) and hematologic malignancies[1][2][3][4][5].

Other names: TGRX 1942TGRX1942TGRX-1942

Targets

PTK7 (Protein tyrosine kinase 7)

Beyond the preview

Go deeper on TGRX-1942.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TGRX-1942.

Explore the full profile